Want to see SE:NICA full AI Analyst Report?
Top Page
Nanologica AB
(NICA)
Select Model
Select Model
Rating:52Neutral
Price Target:
kr0.37
▼(-49.46% Downside)
Action:Reiterated
Date:09/06/26
The score is mainly supported by accelerating revenue growth and a strengthened balance sheet, but is capped by persistent operating losses and negative cash flow. Technically, the stock remains in a downtrend (below major moving averages with negative MACD), while valuation looks optically cheap on P/E.
Positive Factors
Accelerating Revenue
Rapid TTM revenue growth indicates improving commercial traction and suggests that Nanologica is gaining adoption for its offerings. If this momentum continues through customer expansion and scale-up, it can provide a stronger base for operating leverage and future investment in the business.
Negative Factors
Persistent Operating Losses
Deeply negative gross and operating profit show that revenue growth has not yet translated into a sustainable operating model. Continued losses can limit reinvestment capacity and indicate that pricing, production economics, or the cost base must improve before growth produces durable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating Revenue
Rapid TTM revenue growth indicates improving commercial traction and suggests that Nanologica is gaining adoption for its offerings. If this momentum continues through customer expansion and scale-up, it can provide a stronger base for operating leverage and future investment in the business.
Read all positive factors
Nanologica AB (NICA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr113.75M
Dividend YieldN/A
Average Volume (3M)734.99K
Price to Earnings (P/E)1.0
Beta (1Y)1.81
Revenue Growth163.58%
EPS GrowthN/A
CountrySE
Employees72
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.35
Shares Outstanding328,769,840
10 Day Avg. Volume1,511,276
30 Day Avg. Volume734,994
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.04
Price to Sales (P/S)3.26
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr141.40M
Nanologica AB Business Overview & Revenue Model
Company Description
Nanologica AB (publ), a nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science industry in China, India, the United State of America, and internationally. It offers NLAB Saga, a new generation silica...
How the Company Makes Money
Nanologica makes money primarily by selling its nanostructured silica-based products and related services to customers in pharma and life science workflows.
Key revenue streams:
1) Product sales (chromatography media / silica materials): Revenue ...
Nanologica AB Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
56
Neutral
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 53.80M | 21.13M | 14.54M | 1.44M | 1.55M | 12.91M |
| Gross Profit | -53.98M | -49.40M | 4.29M | -76.00K | 3.23M | 4.92M |
| EBITDA | -36.71M | -34.55M | -45.17M | -62.12M | -38.36M | -31.13M |
| Net Income | 18.76M | -51.29M | -65.63M | -75.16M | -55.09M | -50.13M |
Balance Sheet | ||||||
| Total Assets | 243.59M | 88.11M | 143.10M | 77.43M | 154.51M | 98.32M |
| Cash, Cash Equivalents and Short-Term Investments | 19.06M | 3.55M | 48.43M | 10.05M | 70.32M | 11.70M |
| Total Debt | 53.63M | 21.47M | 50.94M | 666.00K | 4.69M | 9.79M |
| Total Liabilities | 87.16M | 65.47M | 68.99M | 79.33M | 81.36M | 46.72M |
| Stockholders Equity | 156.43M | 22.64M | 74.11M | -1.90M | 73.16M | 51.60M |
Cash Flow | ||||||
| Free Cash Flow | -58.33M | -40.88M | -81.48M | -56.83M | -53.78M | -53.74M |
| Operating Cash Flow | -56.86M | -39.88M | -80.73M | -35.85M | -45.22M | -46.49M |
| Investing Cash Flow | -5.36M | -1.08M | -742.00K | -20.35M | -7.14M | -7.25M |
| Financing Cash Flow | 23.40M | -3.21M | 120.23M | -4.09M | 111.70M | -1.64M |
Nanologica AB Technical Analysis
Negative
0.74
Price Trends
0.44
Negative
0.51
Negative
0.53
Negative
Market Momentum
-0.03
Positive
33.01
Neutral
10.85
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NICA, the sentiment is Negative. The current price of 0.74 is above the 20-day moving average (MA) of 0.40, above the 50-day MA of 0.44, and above the 200-day MA of 0.53, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 33.01 is Neutral, neither overbought nor oversold. The STOCH value of 10.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:NICA.
Nanologica AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | kr35.76B | 51.27 | 15.54% | ― | <0.01% | -6.75% | |
52 Neutral | kr113.75M | 0.98 | 23.67% | ― | 163.58% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr929.91M | -41.73 | -22.38% | ― | 104.76% | 37.08% | |
49 Neutral | kr215.33M | -4.21 | -13.41% | ― | -68.66% | -137.27% | |
48 Neutral | kr82.63M | -2.32 | -106.23% | ― | -97.37% | 25.28% | |
41 Neutral | kr452.83M | -2.51 | -26.00% | ― | ― | 44.46% |
* Healthcare Sector Average
SE:NICA
Nanologica AB
0.34
-0.81
-70.48%
SE:CAMX
Camurus AB
584.00
-105.00
-15.24%
SE:XBRANE
Xbrane Biopharma AB
10.10
-20.67
-67.18%
SE:XSPRAY
Xspray Pharma AB
9.67
-39.63
-80.39%
SE:SPAGO
Spago Nanomedical AB
0.11
-0.06
-35.88%
SE:NANEXA
Nanexa AB
5.63
3.37
149.12%
Nanologica AB Corporate Events
Nanologica Boosts Revenue on Syntagon Acquisition Amid CFO Transition
Aug 31, 2026
Nanologica AB reported a sharp increase in net sales in the second quarter of 2026 to SEK 24.3 million from SEK 2.3 million a year earlier, and SEK 45.8 million for the half-year, largely driven by the consolidation of Syntagon. Despite the revenu...
Nanologica Delays Q2 Report Amid Syntagon Integration
Aug 17, 2026
Nanologica AB has postponed the publication of its Q2 2026 interim report to 31 August from the previously scheduled 20 August. The delay is due to extended validation work on the consolidated financial statements following the company’s acq...
Nanologica Names Axel Elner as CFO Ahead of Commercial Expansion
Aug 11, 2026
Nanologica AB has appointed Axel Elner as its new chief financial officer, effective 10 November 2026, succeeding Eva Osterman, who leaves the company at the end of August. Elner brings extensive experience from Viaplay Group and Allente Nordic, w...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.